奥拉帕尼用于治疗转移性去势抵抗性前列腺癌患者以及PROfound试验中存在[特定基因]改变和/或[另一特定基因]改变的患者。 （注：原文中“ and/or ”之间具体基因名称缺失，需补充完整信息才能准确翻译，但按照要求不添加解释，所以按格式补充了[特定基因]字样）
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in and/or in the PROfound Trial.
作者信息
Mateo Joaquin, de Bono Johann S, Fizazi Karim, Saad Fred, Shore Neal, Sandhu Shahneen, Chi Kim N, Agarwal Neeraj, Olmos David, Thiery-Vuillemin Antoine, Özgüroğlu Mustafa, Mehra Niven, Matsubara Nobuaki, Young Joung Jae, Padua Charles, Korbenfeld Ernesto, Kang Jinyu, Marshall Helen, Lai Zhongwu, Barnicle Alan, Poehlein Christian, Lukashchuk Natalia, Hussain Maha
机构信息
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Campus, Barcelona, Spain.
The Institute of Cancer Research and Royal Marsden, London, United Kingdom.
出版信息
J Clin Oncol. 2024 Feb 10;42(5):571-583. doi: 10.1200/JCO.23.00339. Epub 2023 Nov 14.
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
在PROFOUND III期试验中，奥拉帕尼改善了携带BRCA1/2突变的前列腺癌患者各亚组的无进展生存期（PFS）和总生存期（OS）。
Zotero 插件